Navigation Links
Anesiva Receives Positive Nasdaq Hearing Panel Determination for Continued Listing
Date:11/9/2009

ks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. The forward-looking statements contained herein involve risks and uncertainties that could cause actual results to differ materially from those referred to or implied in the forward-looking statements. Such risks include, but are not limited to, the risk that Anesiva otherwise fails to comply with the continued listing requirements of The NASDAQ Global Market or any other NASDAQ market; the risk that the parties to the Merger will be unable to satisfy the conditions to closing the Merger or otherwise complete the Merger; the risk of whether certain market segments grow as anticipated; clinical trial results; the competitive environment in the biotechnology industry; and whether the Anesiva can successfully develop new products and the degree to which these gain market acceptance as well as other risks detailed from time to time in Anesiva's filings with the SEC, including Anesiva's most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2008, its Quarterly Reports on Form 10-Q and its Current Reports on Form 8-K as filed with the SEC. Anesiva expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Anesiva's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

SOURCE Anesiva, Inc.


'/>"/>
SOURCE Anesiva, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication
2. Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring
3. Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company
4. Anesiva Commences Phase 2 Trial of Adlea(TM) in Arthroscopic Shoulder Surgery
5. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
6. Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
7. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
8. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
9. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
10. Anesiva Defines Regulatory Pathway for Adlea with FDA
11. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014  eRelevance Corporation ( www.erelevancecorp.com ), ... that it has completed integration with Nextech, a ... Surgery and Dermatology practices. "Integration allows ... healthcare practices using Nextech," stated Bob Fabbio ... information from the EMR we are able to ...
(Date:8/21/2014)... 2014  Decision Resources Group finds that, for ... Brazil and Mexico ... prescribe long-acting beta-agonist (LABA)- and long-acting muscarinic antagonist ... current severe cost/coverage constraints. Therefore, new brands of ... launch in these countries—which will considerably expand the ...
(Date:8/21/2014)...  Zacks.com announces the list of stocks featured in the ... the latest news and events impacting stocks and the financial ... HPQ - Free Report ), IBM (NYSE: IBM ... - Free Report ), GlaxoSmithKline plc (NYSE: GSK - ... - Free Report ). Today, Zacks is promoting ...
Breaking Medicine Technology:eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 2The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 4The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 5The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 6The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 7The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 8The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 9The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 10The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 11
... Inc., a privately-held developer and marketer of the VerifyNow ... for measuring platelet reactivity to multiple antiplatelet agents, announced ... Portola Pharmaceuticals, Inc. to develop and supply the VerifyNow ... The VerifyNow System is widely used by practicing ...
... SUNNYVALE, Calif., March 2, 2011 Pharmacyclics, Inc. (Nasdaq: ... of PCI-45292, a Btk inhibitor with exceptionally potent anti-arthritis ... results from the current set of preclinical toxicology studies. ... candidate identified within approximately 6 months. ...
Cached Medicine Technology:Accumetrics Signs Development & Supply Agreement With Portola Pharmaceuticals, Inc. 2Update on Preclinical Finding and Development Timeline for PCI-45292 2Update on Preclinical Finding and Development Timeline for PCI-45292 3
(Date:8/21/2014)... 21, 2014 Living in a quality ... that comes along with it. A quality Home Owners ... such amenities are available. , Simpson ... Georgia and Community Association Management, LLC made a recent ... Company to provide an additional amenity for their neighborhood. ...
(Date:8/21/2014)... arteries of chronic kidney disease patients may be a ... new study in the Journal of the American ... the Johns Hopkins Bloomberg School of Public Health assert ... of subclinical atherosclerosis in predicting the risk of heart ... percent of all patients with chronic kidney disease (CKD) ...
(Date:8/21/2014)... Dallas, TX (PRWEB) August 21, 2014 ... August 20 entertained residents with dementia at Silverado Turtle ... Improv Troupe, which consists of entertainers ranging from ages ... each time they perform their 40-minute set. The troupe's ... makes it universal and allows them to touch audiences ...
(Date:8/21/2014)... August 21, 2014 The City of ... for entertainment and programming for its inaugural “Re:Imagine Garden ... October 12, 2014, from 11 a.m. to 4 p.m., ... all cars and the downtown will be filled with ... by Community Arts Resources (CARS), for all to enjoy. ...
(Date:8/21/2014)... Among seniors, dimming vision may be tied to poorer survival, ... people, aged 65 to 84, who were assessed when they ... years later. Vision loss over time was associated with ... study period, the researchers reported. Although the study couldn,t ... Purdue University in West Lafayette, Ind., offered up some theories ...
Breaking Medicine News(10 mins):Health News:Recreation is the Heart of the Community at Simpson Mill Plantation; Chooses American Parks Company™ for New Playground Equipment 2Health News:Recreation is the Heart of the Community at Simpson Mill Plantation; Chooses American Parks Company™ for New Playground Equipment 3Health News:Measuring calcium buildup to predict heart disease in those with chronic kidney disease 2Health News:Unicorn Clearance Improv Troupe Brings Laughter to Residents with Dementia at Silverado Memory Care 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 3Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 4Health News:Failing Vision Tied to Shorter Lifespans for Seniors 2
... new study by Ohio State University researchers has shown ... are not being managed appropriately.,The researchers who looked at ... patients' own descriptions of anxiety after a heart attack ... doctors do not match. In the group of,participants it ...
... been found for detecting upper urinary tract transitional cell ... Canada. This method checks for fibrinogen/fibrin degradation products. It ... to standard urinary cytology. The Researchers compared the efficacy ... cytology in establishing the diagnosis// of transitional cell carcinoma ...
... came up in 1971 argued that people react to ... eventually return to a stable level of well-being. Researchers ... France and England confirmed this theory based on a ... on life satisfaction. 24,000 individuals were followed for 15 ...
... first of its kind study compared a group of whiplash patients ... who suffered a whiplash injury had pain in the neck, head, ... a year. In the study of the two groups, pain in ... a month while in the whiplash injury group patients were still ...
... Examination Survey has now uncovered a link between Periodontal ... of gum disease that causes infection and inflammation of ... of the study where divided into two groups, depending ... an indicator of the presence of periodontal disease. They ...
... Live cancer is one of the most aggressive cancers worldwide ... countries due to hepatitis infection and aflatoxin contamination of foodstuffs. ... Researchers in the US and China have been studying gene ... and found a way of detecting tumors that spread. They ...
Cached Medicine News:
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Fenestrated large type 1/1 (mm), opening width 8.0 mm and length 7.5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Fenestrated large type 1/1 (mm), opening width 7.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 10.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 9 mm....
Medicine Products: